Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
THT 2025: GSN Ablation in HFpEF
Author(s): Marat Fudim Added: 1 year ago
THT Conference 2025 - Findings show catheter ablation of the right greater splanchnic nerve (GSN) in patients with heart failure with preserved ejection fraction (HFpEF) reduced estimated stressed blood volume in patients whether the ablation caused clinical benefits or not. This outcome indicates a confirmation of technical success that correlates with prior single-arm study findings.Dr Marat… View more

Heart Failure
Plaque Burden on CCTA Predicts MACE in Early CAD
Added: 1 month ago Source:  Radcliffe Vascular
A post hoc analysis of the PROMISE trial has found that quantitative coronary plaque measures derived from coronary computed tomographic angiography (CCTA) can independently predict major adverse cardiovascular events (MACE) in symptomatic patients without a known history of coronary artery disease (CAD).¹ The findings suggest that total plaque burden and noncalcified plaque burden may enhance… View more

Imaging & Diagnostics

Prevention & Chronic Conditions
Cardio-obstetrics in the CICU: An Introductory Guide
Author(s): Jenna Skowronski , Eleanor Christenson , Kayle Shapero , et al Added: 1 year ago

CV Disease in Special Populations

Heart Failure
Cardiogenic Shock in Restrictive Cardiomyopathies
Author(s): Ossama K Abou Hassan , Ebere Chukwu , John Schmittner , et al Added: 8 months ago

Heart Failure
AI in Quantitative CT Assessments: CONFIRM2 with Dr Alexander Van Rosendael
Author(s): Alexander van Rosendael , Dipti Itchhaporia Added: 1 year ago
In this episode of the "Innovations in Cardiology" series, host Dr Dipti Itchhaporia (Hoag Heart and Vascular Institute, Newport Beach, CA, US) is joined by Dr Alexander Van Rosendael (Leiden University Medical Center, Leiden, NL) to discuss the findings from the CONFIRM2 trial. Conducted from up to 50 international clinical CCTA sites with 35,000 patients, CONFIRM2 aims to improve comprehensive… View more

Digital Health

Intervention
ACC 25: The EKSTROM Trial
Author(s): Matthew J Budoff Added: 1 year ago
ACC 2025 - Outcomes from colchicine in patients with stable coronary artery disease (CAD) shows significant plaque volume progression compared to placebo at one year.Dr Matthew Budoff (UCLA Medical Centre, Los Angeles, US) joins us onsite at ACC 2025 to discuss findings from the randomized, placebo-controlled, investigator-initiated EKSTROM trial (NCT06342609; Lundquist Institute for Biomedical… View more

Intervention
ACC 25 Late-Breaking Discussion: The ADVANCE-HTN Trial
Author(s): Harriette Van Spall , Luke Laffin Added: 1 year ago
ACC 25 - ADVANCE-HTN shows lorundrostat, an aldosterone synthase inhibitor, effectively lowered 24-hour blood pressure in patients with uncontrolled and true resistant hypertension.Late-breaker discussion host, Dr Harriette Van Spall (McMaster University, Hamilton, CA) is joined by Dr Luke Laffin (Cleveland Clinic, Cleveland, OH, US) to discuss the key findings from the ADVANCE-HTN trial… View more

Prevention & Chronic Conditions
ACC 26: MOMENTUM – Hypercortisolism in Resistant Hypertension
Author(s): Deepak L Bhatt Added: 3 weeks ago
American College of Cardiology Congress 2026 – Dr Deepak Bhatt (Mount Sinai Fuster Heart Hospital, New York, US) joins us to discuss primary results from the MOMENTUM study (NCT06829537; Corcept Therapeutics) investigating the prevalence and clinical impact of endogenous hypercortisolism in patients with resistant hypertension.This prospective, cross-sectional observational study enrolled 1,143… View more

Prevention & Chronic Conditions

Cardiovascular Kidney Metabolic
AHA 25 Late-breaking Discussion: The BETTER-BP Trial
Author(s): John Dodson , Harriette Van Spall Added: 5 months ago
AHA Scientific Sessions 2025 — Late-breaker host Dr Harriette Van Spall (McMaster University, Hamilton, CA) is joined by BETTER-BP Principal Investigator Dr John Dodson (NYU Langone Health, New York, US) to present the findings of this AHA late-breaking trial (NCT04114669).The BETTER-BP (Behavioral Economics Trial to Enhance Regulation of Blood Pressure) is a phase II pragmatic randomized… View more

Prevention & Chronic Conditions
Luke Laffin
Research Area(s) / Expertise: Job title: Preventive Cardiologist
Dr Luke Laffin is a physician in the Preventive Cardiology & Rehabilitation Section in the Robert and Suzanne Tomsich Department of Cardiovascular Medicine, Sydell and Arnold Miller Family Heart & Vascular Institute. He sees patients at Cleveland Clinic main campus and is the medical director of cardiac rehabilitation. Specialty Interests: Cardiology, preventive cardiology, hypertension (high… View more